Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 8/20 | 0.49 |
| ▸ | FECH | P22830 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | IDH2 | P48735 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5163065 | 1.00 | CHEK1 (0.49) | CHEK1FECHKCNH2IDH2TSHR | |
| SCHEMBL5163178 | 1.00 | CHEK1 (0.49) | CHEK1FECHKCNH2IDH2TSHR | |
| SCHEMBL13997114 | 0.92 | IDH2 (0.47) | CHEK1FECHKCNH2IDH2TSHR | |
| Hydrochloric Acid SCHEMBL5063346 | 0.91 | IDH2 (0.47) | CHEK1FECHKCNH2IDH2TSHR | |
| SCHEMBL2033685 | 0.89 | CHEK1 (0.53) | CHEK1FECHKCNH2SCN9A | |
| SCHEMBL13997115 | 0.86 | CHEK1 (0.48) | CHEK1FECHKCNH2IDH2SCN9A | |
| Hydrochloric Acid SCHEMBL5059305 | 0.85 | CHEK1 (0.47) | CHEK1FECHKCNH2IDH2SCN9A | |
| SCHEMBL5164315 | 0.85 | IDH2 (0.46) | CHEK1FECHKCNH2IDH2TSHR | |
| Hydrochloric Acid SCHEMBL5167078 | 0.84 | TSHR (0.43) | CHEK1KCNH2IDH2TSHRRAF1 | |
| SCHEMBL5164330 | 0.83 | CHEK1 (0.43) | CHEK1FECHKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101006075-A | Bisarylurea derivatives useful for inhibiting CHK1 | ICOS CORP (US) | 2007-07-25 | — | — | CN | claimed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| CN-101006075-A | Bisarylurea derivatives useful for inhibiting CHK1 | ICOS CORP (US) | 2007-07-25 | — | — | CN | disclosed |
| EP-1765808-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-03-28 | — | — | EP | disclosed |
| CN-1882342-A | Use of CHK1 inhibitors to control cell proliferation | ICOS CORP (US) | 2006-12-20 | — | — | CN | disclosed |
| EP-1667684-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2006012308-A1 | BISARYLUREA DERIVATIVES USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | CHEK1 1/4885FECH 1861/4885KCNH2 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.